Patents Assigned to Omrix Biopharmaceuticals Ltd.
  • Patent number: 11045588
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 29, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 11020100
    Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 1, 2021
    Assignees: Omrix Biopharmaceuticals, Ltd., Ethicon, Inc.
    Inventors: Ashley DeAnglis, Yair Pilpel, Yuri Zherdev, Sivan Doron, Lior Erez
  • Patent number: 11020101
    Abstract: The invention relates to a device suitable for application of a curable fluid composition to encircle a bodily organ. The device comprises a monolithic piece of a flexible material having a length dimension with an inner surface and an outer surface, a first end and a second end, a width dimension, and two spaced-apart sides, wherein a portion of the length dimension proximal to the first end is configured to contact a portion of the length dimension proximal to the second end, the inner surface defining a hollow area between the two spaced-apart sides; and at least one inlet providing fluid communication between the outer surface and the inner surface, for introduction of the fluid into the hollow area.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 1, 2021
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Yotam Gurman, Moti Meron
  • Patent number: 11009513
    Abstract: The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: May 18, 2021
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Elena Grimberg, Roberto Meidler, Yonit Tiberman, Nadav Orr, Nadav Ashkenazy
  • Patent number: 11007301
    Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: May 18, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11008560
    Abstract: Provided is a method for purifying ?-thrombin and for quantifying ?-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified ?-thrombin. The method can also be used for purification and/or quantification of ?-thrombin.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 18, 2021
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Tamar Auerbach-Nevo, Nadav Orr, Israel Nur
  • Patent number: 11007300
    Abstract: The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 18, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11000635
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 11, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 10960021
    Abstract: Provided is a method of enhancing toxicity of a glycolytic dependent compound towards a cell, tissue and/or organ e.g. a diseased cell, tissue and/or organ, the method comprises contacting Oxidized Regenerated Cellulose (ORC) and/or Oxidized Cellulose (OC); and a glycolytic dependent compound with the cell, tissue and/or organ. The ORC and/or OC; and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: March 30, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: James Galloway, Tamara Byk-Tennenbaum, Erez Ilan, Lior Weissman, Sivan Doron, Eve Montia
  • Patent number: 10960105
    Abstract: The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 30, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Publication number: 20210052263
    Abstract: Disclosed are devices and methods suitable for application of a curable fluid composition to a bodily organ, such as to a lower portion of a bodily organ. The device comprises a monolithic piece of material having a lower surface, two spaced-apart sides, and two spaced-apart walls connecting the two spaced-apart sides. A receptacle for containing the curable fluid composition is defined by the lower surface, the two sides, and the two walls. At least a portion of the height of the two walls is less than the height of at least a portion of the two sides. The device is deployable underneath the bodily organ such that a lower portion of the bodily organ is supported by at least a portion of each of the two walls.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 25, 2021
    Applicant: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez ILAN, Yotam GURMAN, Moti MERON
  • Patent number: 10869912
    Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 22, 2020
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Assaf Gershonovitch, Rivka Kaufman
  • Patent number: 10849605
    Abstract: Disclosed are devices and methods suitable for application of a curable fluid composition to a bodily organ, such as to a lower portion of a bodily organ. The device comprises a monolithic piece of material having a lower surface, two spaced-apart sides, and two spaced-apart walls connecting the two spaced-apart sides. A receptacle for containing the curable fluid composition is defined by the lower surface, the two sides, and the two walls. At least a portion of the height of the two walls is less than the height of at least a portion of the two sides. The device is deployable underneath the bodily organ such that a lower portion of the bodily organ is supported by at least a portion of each of the two walls.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: December 1, 2020
    Assignee: Omrix Biopharmaceuticals, Ltd.
    Inventors: Erez Ilan, Yotam Gurman, Moti Meron
  • Patent number: 10806755
    Abstract: Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: October 20, 2020
    Assignee: Omrix Biopharmaceuticals, Ltd.
    Inventors: Roberto Meidler, Elena Grimberg, Oleg Belyaev, Yonit Tiberman, Israel Nur, Tamar Auerbach-Nevo
  • Patent number: 10716548
    Abstract: The invention relates to syringes for storing and mixing components.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 21, 2020
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Yair Pilpel, Sivan Doron, Yuri Zherdev, Lior Erez, Ashley DeAnglis
  • Patent number: 10618950
    Abstract: Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 14, 2020
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Kfir Regev, Dana Leitman, Israel Nur, Moti Meron, John Goodman
  • Patent number: 10555991
    Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: February 11, 2020
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Yair Pilpel, Ashley Deanglis, Yuri Zherdev, Sivan Doron, Anne Gorman, Israel Nur
  • Patent number: 10538754
    Abstract: The present invention is directed to methods for the production of thrombin from a source of prothrombin using a given BaSO4 reagent as an adsorbent of prothrombin as well as methods for evaluating the suitability of a given BaSO4 reagent for use in preparation of thrombin. In at least one embodiment, the method includes contacting a sample of the given BaSO4 reagent with a source of prothrombin to obtain BaSO4-adsorbed prothrombin, and subsequently evaluating the pro-coagulant activity of the BaSO4-adsorbed prothrombin. In another embodiment, the method includes the step of evaluating relative to the pro-coagulant activity of normal mammalian plasma.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: January 21, 2020
    Assignees: Omrix Biopharmaceuticals Ltd.
    Inventors: Lior Weissman, Dana Sella, Israel Nur, Caixia Jiang, Baochang An
  • Patent number: 10479987
    Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: November 19, 2019
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Roberto Meidler, Oleg Belyaev, Liliana Bar, Israel Nur
  • Patent number: 10466258
    Abstract: Provided is a method, device and system for an in-situ preparation of a sample, for example, for use in detecting the presence of, and/or quantifying, clottable fibrinogen in such a sample.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: November 5, 2019
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Elena Grimberg, Roberto Meidler, Yonit Tiberman, Nadav Orr, Nadav Ashkenazy